2016 (v1)
Publication
No description
Uploaded on: April 14, 2023
M
A
Last name: MOSCA
First name: Alessandra
No description
Despite the current immunotherapy era, VEGFR inhibitors maintain effectiveness in metastatic renal cell cancer. Real-world data concerning pazopanib are limited. The aim of this study is to add information about efficacy and safety of pazopanib as first-line treatment in metastatic renal cell cancer patients not enrolled into clinical trials.